Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 13/20 | 0.55 |
| ▸ | CA5A | P35218 | 1/20 | 0.45 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.39 |
| ▸ | CCR1 | P32246 | 1/20 | 0.38 |
| ▸ | CCR2 | P41597 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | DPP4 | P27487 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29820003 | 0.80 | CYP19A1 (0.70) | CYP19A1CCR1CCR2ALDH1A1KDM4E | |
| SCHEMBL12468869 | 0.80 | CYP19A1 (0.70) | CYP19A1CCR1CCR2ALDH1A1KDM4E | |
| SCHEMBL12468796 | 0.79 | CYP19A1 (0.50) | CYP19A1CCR1CCR2DPP4 | |
| SCHEMBL7468845 | 0.75 | CYP19A1 (0.56) | CYP19A1CCR1CCR2DPP4 | |
| SCHEMBL29820311 | 0.74 | CYP19A1 (0.64) | CYP19A1KEAP1CCR1CCR2ALDH1A1 | |
| SCHEMBL28263864 | 0.72 | CYP19A1 (0.68) | CYP19A1CCR1CCR2 | |
| SCHEMBL29820189 | 0.72 | CYP19A1 (0.67) | CYP19A1CCR1CCR2ALDH1A1TSHR | |
| SCHEMBL13201552 | 0.71 | CYP19A1 (0.80) | CYP19A1CCR1CCR2 | |
| SCHEMBL155247 | 0.71 | CYP19A1 (1.00) | CYP19A1CCR1CCR2POLB | |
| Hydrochloric Acid SCHEMBL7263772 | 0.69 | CYP19A1 (0.96) | CYP19A1CCR1CCR2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117105873-A | Preparation method of rufeamide intermediate | 宿州亿帆药业有限公司 | 2023-11-24 | — | — | CN | disclosed |
| CN-117050027-A | Preparation method of rufeamide impurity reference substance | 宿州亿帆药业有限公司 | 2023-11-14 | — | — | CN | disclosed |
| CN-110072521-A | Pharmaceutical combination comprising a T-type calcium channel blocker | 爱杜西亚药品有限公司 | 2019-07-30 | — | — | CN | disclosed |
| CN-107406420-A | Substituted triazoles and methods related thereto | 纽罗克里生物科学有限公司 | 2017-11-28 | — | — | CN | disclosed |
| US-8969556-B2 | Purine-based triazoles | CASE WESTERN RESERVE UNIVERSITY (US) | 2015-03-03 | — | — | US | disclosed |
| US-20140045866-A1 | PURINE-BASED TRIAZOLES | CASE WESTERN RESERVE UNIVERSITY | 2014-02-13 | — | — | US | disclosed |
| WO-2012051296-A2 | PURINE-BASED TRIAZOLES | CASE WESTERN RESERVE UNIVERSITY (US) | 2012-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140045866-A1 | PURINE-BASED TRIAZOLES | PNP, TK2, NME4 | CYP19A1 4083/4885CA5A 1546/4885KEAP1 3890/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.